Moderna Starts Human Trials Of mRNA Vaccine For Virus That Likely Causes Multiple Sclerosis

Topline

Moderna recently launched early stage clinical trials for an mRNA vaccine against the Epstein-Barr virus (EBV), a common pathogen that infects almost everyone at some point in their lives, is the primary cause of mononucleosis and, according to a study published in the journal Science Thursday, likely causes multiple sclerosis (MS), offering hope the devastating neurological condition might be prevented.

Key Facts

Moderna said it had dosed the first participant in a study designed to test its EBV vaccine in early January, and will evaluate the shot’s safety and dosage in around 270 people. 

If successful, the shot, built using the same mRNA technology in the company’s Covid-19 vaccine, could be the first EBV vaccine on the market.  

The Moderna trial comes at the same time Harvard researchers linked infection with the common virus to MS, a neurological condition affecting some

Keep reading this article on Forbes Business.

Leave a Reply